Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations

Mokaya, Jolynne; Vasylyeva, Tetyana I.; Barnes, Eleanor; Ansari, M Azim; Pybus, Oliver G.; Matthews, Philippa C.

doi:10.1111/jvh.13525

Cited by 16 publications

(11 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infrequent screening, limited supply of antiviral drugs, and poor access to clinical monitoring contribute to the emergence of drug resistance in Africa and highlight the need for continued monitoring in key populations [ 46 ]. Finally, we and others have evaluated the global presence of vaccine escape mutations [ 7 , 46 , 47 ]. Polymorphisms at sites associated with vaccine escape is relatively common; however, it is often not possible to determine if the individuals harboring these polymorphisms or vaccine-escape mutations had been vaccinated against HBV.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B virus genotypes and drug resistance mutations circulating in blood donors in Beira, Mozambique

et al. 2023

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infects nearly 300 million people and is the leading cause of hepatitis and hepatocellular carcinoma worldwide. Despite the high burden of HBV in sub-Saharan Africa, countries such as Mozambique have limited data available on circulating HBV genotypes and the presence of drug resistance mutations. Blood donors from Beira, Mozambique were tested for HBV surface antigen (HBsAg) and HBV DNA at the Instituto Nacional de Saúde in Maputo, Mozambique. Regardless of HBsAg status, donors with detectable HBV DNA were evaluated for HBV genotype. PCR was performed with primers amplifying a 2.1–2.2 kilobase fragment of the HBV genome. PCR products were submitted for next generation sequencing (NGS), and consensus sequences were evaluated for HBV genotype, recombination, and the presence or absence of drug resistance mutations. Of the 1281 blood donors tested, 74 had quantifiable HBV DNA. The polymerase gene could be amplified from 45 of 58 (77.6%) individuals with chronic HBV infection and 12 of 16 (75%) with occult HBV infection. Among these 57, 51 (89.5%) sequences belonged to HBV genotype A1, while 6 (10.5%) were HBV genotype E. All genotype E sequences were E/A recombinants, and clustered separately from other genotype E references. Genotype A samples had a median viral load of 637 IU/mL, while genotype E samples had a median viral load of 476,084 IU/mL. No drug resistance mutations were observed in the consensus sequences. The current study demonstrates the genotypic diversity of HBV in blood donors in Mozambique, but the absence of dominant (consensus) drug resistance mutations. Studies in other at-risk populations are essential for understanding the epidemiology, risk of liver disease, and likelihood of treatment resistance in resource-limited settings.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis B virus genotypes and drug resistance mutations circulating in blood donors in Beira, Mozambique

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The neutralizing activity of our mAbs needs to be evaluated more rigorously because we only showed its superiority over HBIG, a polyclonal antibody that contains many antibodies other than the target‐neutralizing antibody. In addition, it is also necessary to evaluate whether the obtained mAbs have a sufficient neutralizing effect against drug resistance‐associated mutations and vaccine escape mutations, which are an increasing concern worldwide 27 . To develop these mAbs as pharmaceuticals will require further optimization of qualities such as solubility and viscosity at high concentrations, glycosylation status, clearance rates, and others 28–30 …”

Section: Discussionmentioning

confidence: 99%

Development of a recombinant hepatitis B immunoglobulin derived from B cells collected from healthy individuals administered with hepatitis B virus vaccines: A feasibility study

et al. 2023

View full text Add to dashboard Cite

Background: In Japan, plasma with a high concentration of Hepatitis B Virus (HBV) antibodies for hepatitis B immunoglobulin (HBIG) is almost entirely imported. We aimed to produce recombinant HBIG by isolating immunoglobulin cDNAs against the HBV surface antigen (HBsAg). Study Design and Methods: B cells expressing HBsAg antibodies were obtained from blood center personnel who had been administered HB vaccine booster and then isolated by either an Epstein-Barr virus hybridoma or an antigen-specific memory B cell sorting method. Each cDNA of the heavy and light chains of the target antibody was cloned into an IgG 1 expression vector and transfected into Expi293F cells to produce a recombinant monoclonal antibody (mAb), which was screened by ELISA and in vitro HBV neutralizing assays. The cross-reactivity of the mAbs to normal human molecules was evaluated by ELISA and immunohistochemistry.Results: Antibody cDNAs were cloned from 11 hybridoma cell lines and 204 HBsAg-bound memory B cells. Three of the resulting recombinant mAbs showed stronger neutralizing activity in vitro than the currently used HBIG. All three bind to the conformational epitope(s) of HBsAg but not to human DNA or cells. Discussion: We successfully isolated HBV-neutralizing monoclonal antibodies from B cells collected from healthy plasma donors boosted against the HBV.

show abstract

“…3 Multiple host and viral factors can lead to intrahost virus mutation. 4 HBV DNA mutations can affect the natural course of infection, disease progression, and treatment response in patients with chronic infection, including occult HBV infection, 5 vaccine escape, 6 drug resistance, 7 and poor prognosis. 8 Hence, exploring HBV DNA mutations is important for clinicians to comprehensively evaluate the patient's condition and adjust the treatment if needed.…”

Section: Introductionmentioning

confidence: 99%

Global status and trends in hepatitis B virus DNA mutation research from 2003 to 2022: A comprehensive bibliometric view

Li,

Xu,

Liu

et al. 2024

Portal Hypertension & Cirrhosis

View full text Add to dashboard Cite

AimsHepatitis B virus (HBV) is an enveloped DNA virus belonging to the Hepadnaviridae family. It is a significant contributor to the prevalence of chronic liver disease on a global scale. Mutations in HBV DNA can affect the diagnosis, treatment, and prognosis of patients with chronic hepatitis B. Although numerous studies on HBV DNA mutations have been conducted, few bibliometric studies have been performed to date. This study aimed to analyze changes in scientific output to gain a better understanding of the current research status and identify potential new research directions in the field of HBV DNA mutation.MethodsRelevant studies published between 2003 and 2022 were retrieved from the Web of Science Core Collection database. CiteSpace version 6.1.R6 was used to construct network maps to evaluate collaborations among countries, institutions, authors, journals, and keywords.ResultsIn total, 1508 publications over the past 20 years were obtained, mainly from China, the United States, and Japan. The major research institutions in China included the University of Hong Kong, Fudan University, and Peking University. Lai Ching Lung was the most productive author, whereas Anna Suk‐Fong Lok was the most frequently co‐cited author. The keyword “HBsAg” was the strongest burst keyword in recent years, indicating possible future study trends.ConclusionsThis bibliometric analysis intuitively revealed the overall research status of HBV DNA mutations, providing valuable information for researchers, funding agencies, and policymakers to explore the current research status, research hotspots, and new directions for future research.

show abstract

Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 16 publications

References 67 publications

Hepatitis B virus genotypes and drug resistance mutations circulating in blood donors in Beira, Mozambique

Hepatitis B virus genotypes and drug resistance mutations circulating in blood donors in Beira, Mozambique

Development of a recombinant hepatitis B immunoglobulin derived from B cells collected from healthy individuals administered with hepatitis B virus vaccines: A feasibility study

Global status and trends in hepatitis B virus DNA mutation research from 2003 to 2022: A comprehensive bibliometric view

Contact Info

Product

Resources

About